Metastatic Epidural, Spinal Cord, Spine Stereotactic
Conditions
Brief summary
To learn about the safety of a procedure called cord dose escalated spine stereotactic radiosurgery (CDE-SSRS) in patients with MESCC.
Detailed description
Primary Objectives The primary protocol objectives are to establish the safety of CDE-SSRS alone in participants with MESCC. Specifically, we aim to maintain an RM risk no greater than 1%. RM will be defined as non-functional paresis per the McCormick score (i.e., Grade D). Secondary Objectives Secondary objectives include pain control as measured by the Brief Pain Inventory, quality of life as measured by the EQ-5D, symptom burden as measured by the MDASI-SP, overall survival, toxicity, ambulatory rate and cost-effectiveness. LC will be defined radiographically with serial MRI scans by the study radiologist per SPINO criteria.
Interventions
RADIATIONStereotactic Radiosurgery
Given by RTx
Sponsors
M.D. Anderson Cancer Center
Brainlab AG
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Greater than or equal to 18 years old 2. Radiographically documented spinal metastasis on spine MRI within 4 weeks of registration 3. Proximity of spinal metastasis to spinal cord or cauda equina which precludes achieving a GTV Dmin of at least 14 Gy per the PI 4. All participants must be able to receive single fraction SSRS at the site of interest with 0.01 cc of the spinal cord receiving 14-16 Gy and/or 0.01 cc of the cauda equina receiving 18-20 Gy. The goal of treatment is to select the minimal dose to the organ at risk which will achieve a GTV Dmin of 14 Gy at the treating physician's discretion. 5. Maximum of 3 contiguous vertebral levels involved with metastasis in the spine to be irradiated in a single session 6. All participants must be able to receive a single fraction spine radiosurgery at the designated site of interest to at least a dose of 18 Gy 7. All participants must have a vertebral level site of interest from C1 to S2 8. Signed informed consent 9. Diagnosis of cancer excluding ultra-radiosensitive histologies (see 4.2) 10. Motor strength ≥ 4 out of 5 in extremity or extremities affected by the level of cord compression 11. ECOG ≤ 2
Exclusion criteria
1. Participants with ultra-radiosensitive histologies (lymphoma, multiple myeloma/plasmacytoma) 2. Prior history of radiation at the spinal site of interest 3. Inability to lie supine comfortably for ≥ 60 minutes 4. Progressive neurological deficits due to compression 5. Inability of obtain an MRI 6. Inability or refusal to undergo an MR simulation 7. No eligible for single fraction SSRS for any reason 8. Participants who are pregnant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and adverse events (AEs) | Through study completion; an average of 1 year. | Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 |
Countries
United States
Contacts
CONTACTAmol Ghia, MD
PRINCIPAL_INVESTIGATORAmol Ghia, MD
M.D. Anderson Cancer Center
Outcome results
None listed